We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 22, 2021

Apalutamide + ADT for Metastatic Castration-Sensitive Prostate Cancer

The Journal of Urology


Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Urology
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study
J Urol 2021 Oct 01;206(4)914-923, N Agarwal, K McQuarrie, A Bjartell, S Chowdhury, AJ Pereira de Santana Gomes, BH Chung, M Özgüroğlu, Á Juárez Soto, AS Merseburger, H Uemura, D Ye, R Given, E Basch, B Miladinovic, A Lopez-Gitlitz, KN Chi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading